Literature DB >> 34505365

Initial treatment choices to achieve sustained response in major depression: a systematic review and network meta-analysis.

Toshi A Furukawa1, Kiyomi Shinohara1, Ethan Sahker1, Eirini Karyotaki2, Clara Miguel2, Marketa Ciharova2, Claudi L H Bockting3, Josefien J F Breedvelt3, Aran Tajika1, Hissei Imai1, Edoardo G Ostinelli4,5, Masatsugu Sakata1, Rie Toyomoto1, Sanae Kishimoto1, Masami Ito1, Yuki Furukawa6, Andrea Cipriani4,5, Steven D Hollon7, Pim Cuijpers2.   

Abstract

Major depression is often a relapsing disorder. It is therefore important to start its treatment with therapies that maximize the chance of not only getting the patients well but also keeping them well. We examined the associations between initial treatments and sustained response by conducting a network meta-analysis of randomized controlled trials (RCTs) in which adult patients with major depression were randomized to acute treatment with a psychotherapy (PSY), a protocolized antidepressant pharmacotherapy (PHA), their combination (COM), standard treatment in primary or secondary care (STD), or pill placebo, and were then followed up through a maintenance phase. By design, acute phase treatment could be continued into the maintenance phase, switched to another treatment or followed by discretionary treatment. We included 81 RCTs, with 13,722 participants. Sustained response was defined as responding to the acute treatment and subsequently having no depressive relapse through the maintenance phase (mean duration: 42.2±16.2 weeks, range 24-104 weeks). We extracted the data reported at the time point closest to 12 months. COM resulted in more sustained response than PHA, both when these treatments were continued into the maintenance phase (OR=2.52, 95% CI: 1.66-3.85) and when they were followed by discretionary treatment (OR=1.80, 95% CI: 1.21-2.67). The same applied to COM in comparison with STD (OR=2.90, 95% CI: 1.68-5.01 when COM was continued into the maintenance phase; OR=1.97, 95% CI: 1.51-2.58 when COM was followed by discretionary treatment). PSY also kept the patients well more often than PHA, both when these treatments were continued into the maintenance phase (OR=1.53, 95% CI: 1.00-2.35) and when they were followed by discretionary treatment (OR=1.66, 95% CI: 1.13-2.44). The same applied to PSY compared with STD (OR=1.76, 95% CI: 0.97-3.21 when PSY was continued into the maintenance phase; OR=1.83, 95% CI: 1.20-2.78 when PSY was followed by discretionary treatment). Given the average sustained response rate of 29% on STD, the advantages of PSY or COM over PHA or STD translated into risk differences ranging from 12 to 16 percentage points. We conclude that PSY and COM have more enduring effects than PHA. Clinical guidelines on the initial treatment choice for depression may need to be updated accordingly.
© 2021 World Psychiatric Association.

Entities:  

Keywords:  Major depression; cognitive behavioral therapy; combination therapy; maintenance treatment; network meta-analysis; pharmacotherapy; psychotherapy; sustained response; treatment choice

Year:  2021        PMID: 34505365      PMCID: PMC8429344          DOI: 10.1002/wps.20906

Source DB:  PubMed          Journal:  World Psychiatry        ISSN: 1723-8617            Impact factor:   49.548


  44 in total

1.  Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry.

Authors:  Jaime L Peters; Alex J Sutton; David R Jones; Keith R Abrams; Lesley Rushton
Journal:  J Clin Epidemiol       Date:  2008-06-06       Impact factor: 6.437

Review 2.  Recognition of psychotherapy effectiveness: the APA resolution.

Authors:  Linda F Campbell; John C Norcross; Melba J T Vasquez; Nadine J Kaslow
Journal:  Psychotherapy (Chic)       Date:  2013-03

3.  Can we help more?

Authors:  Robin B Jarrett
Journal:  World Psychiatry       Date:  2020-06       Impact factor: 49.548

Review 4.  Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review.

Authors:  John R Geddes; Stuart M Carney; Christina Davies; Toshiaki A Furukawa; David J Kupfer; Ellen Frank; Guy M Goodwin
Journal:  Lancet       Date:  2003-02-22       Impact factor: 79.321

5.  Targets and outcomes of psychological interventions: implications for guidelines and policy.

Authors:  Mark van Ommeren
Journal:  World Psychiatry       Date:  2019-10       Impact factor: 49.548

6.  Sequential Combination of Pharmacotherapy and Psychotherapy in Major Depressive Disorder: A Systematic Review and Meta-analysis.

Authors:  Jenny Guidi; Giovanni A Fava
Journal:  JAMA Psychiatry       Date:  2021-03-01       Impact factor: 21.596

7.  Continuation of Antidepressants vs Sequential Psychological Interventions to Prevent Relapse in Depression: An Individual Participant Data Meta-analysis.

Authors:  Josefien J F Breedvelt; Fiona C Warren; Zindel Segal; Willem Kuyken; Claudi L Bockting
Journal:  JAMA Psychiatry       Date:  2021-08-01       Impact factor: 21.596

8.  Does cognitive behaviour therapy have an enduring effect that is superior to keeping patients on continuation pharmacotherapy? A meta-analysis.

Authors:  Pim Cuijpers; Steven D Hollon; Annemieke van Straten; Claudi Bockting; Matthias Berking; Gerhard Andersson
Journal:  BMJ Open       Date:  2013-04-26       Impact factor: 2.692

9.  Dismantling, optimising, and personalising internet cognitive behavioural therapy for depression: a systematic review and component network meta-analysis using individual participant data.

Authors:  Toshi A Furukawa; Aya Suganuma; Edoardo G Ostinelli; Gerhard Andersson; Christopher G Beevers; Jason Shumake; Thomas Berger; Florien Willemijn Boele; Claudia Buntrock; Per Carlbring; Isabella Choi; Helen Christensen; Andrew Mackinnon; Jennifer Dahne; Marcus J H Huibers; David D Ebert; Louise Farrer; Nicholas R Forand; Daniel R Strunk; Iony D Ezawa; Erik Forsell; Viktor Kaldo; Anna Geraedts; Simon Gilbody; Elizabeth Littlewood; Sally Brabyn; Heather D Hadjistavropoulos; Luke H Schneider; Robert Johansson; Robin Kenter; Marie Kivi; Cecilia Björkelund; Annet Kleiboer; Heleen Riper; Jan Philipp Klein; Johanna Schröder; Björn Meyer; Steffen Moritz; Lara Bücker; Ove Lintvedt; Peter Johansson; Johan Lundgren; Jeannette Milgrom; Alan W Gemmill; David C Mohr; Jesus Montero-Marin; Javier Garcia-Campayo; Stephanie Nobis; Anna-Carlotta Zarski; Kathleen O'Moore; Alishia D Williams; Jill M Newby; Sarah Perini; Rachel Phillips; Justine Schneider; Wendy Pots; Nicole E Pugh; Derek Richards; Isabelle M Rosso; Scott L Rauch; Lisa B Sheeber; Jessica Smith; Viola Spek; Victor J Pop; Burçin Ünlü; Kim M P van Bastelaar; Sanne van Luenen; Nadia Garnefski; Vivian Kraaij; Kristofer Vernmark; Lisanne Warmerdam; Annemieke van Straten; Pavle Zagorscak; Christine Knaevelsrud; Manuel Heinrich; Clara Miguel; Andrea Cipriani; Orestis Efthimiou; Eirini Karyotaki; Pim Cuijpers
Journal:  Lancet Psychiatry       Date:  2021-05-03       Impact factor: 77.056

10.  National Prescription Patterns of Antidepressants in the Treatment of Adults With Major Depression in the US Between 1996 and 2015: A Population Representative Survey Based Analysis.

Authors:  Yan Luo; Yuki Kataoka; Edoardo G Ostinelli; Andrea Cipriani; Toshi A Furukawa
Journal:  Front Psychiatry       Date:  2020-02-14       Impact factor: 4.157

View more
  7 in total

Review 1.  Stage models for major depression: Cognitive behavior therapy, mechanistic treatment targets, and the prevention of stage transition.

Authors:  Michael W Otto; Jeffrey L Birk; Hayley E Fitzgerald; Gregory V Chauvin; Alexandra K Gold; Jenna R Carl
Journal:  Clin Psychol Rev       Date:  2022-05-23

2.  Trends in the epidemiology of depression and comorbidities from 2000 to 2019 in Belgium.

Authors:  Roosje Walrave; Simon Gabriël Beerten; Pavlos Mamouris; Kristien Coteur; Marc Van Nuland; Gijs Van Pottelbergh; Lidia Casas; Bert Vaes
Journal:  BMC Prim Care       Date:  2022-06-28

3.  Scale up task-sharing of psychological therapies.

Authors:  Vikram Patel
Journal:  Lancet       Date:  2021-12-17       Impact factor: 79.321

4.  Care pathways for people with major depressive disorder: a European Brain Council Value of Treatment study.

Authors:  Rebecca Strawbridge; Paul McCrone; Andrea Ulrichsen; Roland Zahn; Jonas Eberhard; Danuta Wasserman; Paolo Brambilla; Giandomenico Schiena; Ulrich Hegerl; Judit Balazs; Jose Caldas de Almeida; Ana Antunes; Spyridon Baltzis; Vladimir Carli; Vinciane Quoidbach; Patrice Boyer; Allan H Young
Journal:  Eur Psychiatry       Date:  2022-06-15       Impact factor: 7.156

5.  High depression symptomatology and mental pain characterize suicidal psychiatric patients.

Authors:  Maurizio Pompili; Marco Innamorati; Denise Erbuto; Mario Luciano; Gaia Sampogna; Giovanni Abbate-Daga; Stefano Barlati; Claudia Carmassi; Giovanni Castellini; Pasquale De Fazio; Giorgio Di Lorenzo; Marco Di Nicola; Silvia Ferrari; Arianna Goracci; Carla Gramaglia; Giovanni Martinotti; Maria Giulia Nanni; Massimo Pasquini; Federica Pinna; Nicola Poloni; Gianluca Serafini; Maria Signorelli; Alfonso Tortorella; Antonio Ventriglio; Umberto Volpe; Andrea Fiorillo
Journal:  Eur Psychiatry       Date:  2022-08-31       Impact factor: 7.156

6.  Psychological Status, Compliance, Serum Brain-Derived Neurotrophic Factor, and Nerve Growth Factor Levels of Patients with Depression after Augmented Mindfulness-Based Cognitive Therapy.

Authors:  Huirong Guo; Yuming Ren; Bailing Huang; Junru Wang; Xuhuang Yang; Yali Wang
Journal:  Genet Res (Camb)       Date:  2022-01-04       Impact factor: 1.588

Review 7.  The Contribution of "Individual Participant Data" Meta-Analyses of Psychotherapies for Depression to the Development of Personalized Treatments: A Systematic Review.

Authors:  Pim Cuijpers; Marketa Ciharova; Soledad Quero; Clara Miguel; Ellen Driessen; Mathias Harrer; Marianna Purgato; David Ebert; Eirini Karyotaki
Journal:  J Pers Med       Date:  2022-01-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.